West African Center for Emerging Infectious Diseases
Project Number3U01AI151801-02S1
Contact PI/Project LeaderWEAVER, SCOTT C
Awardee OrganizationUNIVERSITY OF TEXAS MED BR GALVESTON
Description
Abstract Text
Arthropod-borne viruses (arboviruses) such as chikungunya (CHIKV) and Zika (ZIKV), as well as rodent- and
bat-borne viruses such as Lassa fever and probably Ebola, are among the most important causes of emerging
infectious diseases, and many circulate enzootically in W. Africa. The mechanisms whereby these and other
zoonotic African viruses emerge and spread remain obscure, along with the understanding of their disease
burden and varied clinical outcomes. The West African Center for Emerging Infectious Diseases will address
these critical gaps through field studies of enzootic transmission, and clinical studies of human exposure and
disease outcome. Our surveillance of humans, and wild animals, including bats (probable hosts of filoviruses,
coronaviruses and henipaviruses), and mosquitoes/ticks, will likely identify new emerging viral pathogens.
Further, the infrastructure and local expertise developed through these projects in Senegal, Sierra Leone and
Nigeria, along with biosafety/biosecurity training and improved diagnostics, will also prepare the region for
future outbreaks of emerging viral and other infectious diseases. The Center’s aims are to:
1. Study zoonotic arboviruses in Senegal, Sierra Leone and Nigeria, including identification and
characterization of critical reservoir and amplification hosts, enzootic and epidemic vectors, temporal
patterns of enzootic and epidemic circulation, levels of human exposure, immune responses and disease
outcomes. The emphasis will be on the 4 “urban” (human amplified) arboviruses: CHIKV, DENV, YFV and
ZIKV, but other known and possibly unknown viruses will also be studied. Risk maps will be generated.
2. In Sierra Leone and Nigeria, study the circulation among rodent hosts and infections of humans by Lassa
virus, including identification of viral determinants of hemorrhagic disease severity and sequelae outcomes,
and determination of the mechanisms of strain virulence variation. Risk maps will also be generated.
3. Perform surveillance in bats to identify potential sources of Ebola virus in W. Africa as well as other known
or unknown zoonotic pathogens, including coronaviruses and henipaviruses that may be causing human
disease, and which may explain the origins of emerging pathogens such as Nipah and MERS coronavirus.
4. Establish biocontainment and biosecurity training programs, advanced yet affordable viral genomics
capabilities, and comprehensive diagnostics to support these aims as well as to improve research
infrastructure and future outbreak responses in W. Africa.
Our results will increase the mechanistic understanding of zoonotic viral maintenance and emergence,
etiologies of febrile and hemorrhagic diseases, diverse disease outcomes, and risks for local and international
spread. Novel viruses with emergence potential will likely be discovered, and existing collaborations between
the Univ. of TX Medical Branch and its partners in Senegal, Sierra Leone, and Nigeria, as well as research
infrastructure, will be strengthened to prepare for and respond quickly and effectively to future outbreaks.
Public Health Relevance Statement
Project Narrative
Arthropod-borne viruses (arboviruses) such as chikungunya (CHIKV) and Zika (ZIKV), as well as rodent- and
bat-borne viruses such as Lassa fever and probably Ebola, are among the most important causes of emerging
infectious diseases that can spread worldwide to threaten global public health. Many of these viruses originate
in Africa, where they circulate in wildlife and mosquitoes. The West African Center for Emerging Infectious
Diseases will monitor people in Senegal, Nigeria and Sierra Leone to detect infections with these and other
emerging viruses, determine how these people become infected and why disease outcomes vary widely, then
produce risk maps so that surveillance and control can be focused on the most important regions.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAffectAfricaAfricanAmericasAngolaArbovirusesArthralgiaAsiaBlood CirculationCaribbean regionCentral AmericaChikungunya virusChiropteraChronicClinicalClinical ResearchCollaborationsCommunicable DiseasesCoronavirusCountryCulicidaeDengueDiagnosticDiseaseDisease OutbreaksDisease OutcomeEbolaEbola virusElectronic Medical Records and Genomics NetworkEmerging Communicable DiseasesEpidemicEtiologyEuropeFeverFilovirusFloridaFutureGoalsGuillain Barré SyndromeHealth PersonnelHemorrhageHemorrhagic Fever with Renal SyndromeHenipavirusHospitalsHumanImmune System DiseasesImmune responseIndian OceanInfectionInfrastructureInternationalLaboratoriesLassa FeverLassa virusMaintenanceMapsMedicalMexicoMicrocephalyMiddle East Respiratory Syndrome CoronavirusMonitorNigeriaOutcomePatternPublic HealthRNAResearch InfrastructureRiskRodentSenegalSeverity of illnessSierra LeoneSourceSouth AmericaTexasTicksTimeTrainingTraining ProgramsVariantViralViral Hemorrhagic FeversVirulenceVirusVirus DiseasesWild AnimalsYellow FeverZIKAZIKV infectionZika VirusZoonosesbat-bornebiosecurityburden of illnesschikungunyacongenital zika syndromeemerging pathogenenzooticexposed human populationfield studyhuman diseaseimprovednovel viruspathogenpathogenic virusprogramspublic health emergencyresponsetransmission processvectorviral genomics
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
800771149
UEI
MSPWVMXXMN76
Project Start Date
09-June-2020
Project End Date
31-May-2025
Budget Start Date
06-September-2021
Budget End Date
31-May-2023
Project Funding Information for 2021
Total Funding
$521,027
Direct Costs
$438,162
Indirect Costs
$82,865
Year
Funding IC
FY Total Cost by IC
2021
National Institute of Allergy and Infectious Diseases
$521,027
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3U01AI151801-02S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3U01AI151801-02S1
Patents
No Patents information available for 3U01AI151801-02S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3U01AI151801-02S1
Clinical Studies
No Clinical Studies information available for 3U01AI151801-02S1
News and More
Related News Releases
No news release information available for 3U01AI151801-02S1
History
No Historical information available for 3U01AI151801-02S1
Similar Projects
No Similar Projects information available for 3U01AI151801-02S1